ATE409749T1 - Verfahren zur reinigung von alphaviralen replikon partikeln - Google Patents
Verfahren zur reinigung von alphaviralen replikon partikelnInfo
- Publication number
- ATE409749T1 ATE409749T1 AT01941874T AT01941874T ATE409749T1 AT E409749 T1 ATE409749 T1 AT E409749T1 AT 01941874 T AT01941874 T AT 01941874T AT 01941874 T AT01941874 T AT 01941874T AT E409749 T1 ATE409749 T1 AT E409749T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- purifying
- replicon particles
- purification
- disclosed
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 3
- 241000710929 Alphavirus Species 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 238000000746 purification Methods 0.000 abstract 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 abstract 1
- 238000011097 chromatography purification Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003456 ion exchange resin Substances 0.000 abstract 1
- 229920003303 ion-exchange polymer Polymers 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36151—Methods of production or purification of viral material
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20837600P | 2000-05-31 | 2000-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE409749T1 true ATE409749T1 (de) | 2008-10-15 |
Family
ID=22774372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01941874T ATE409749T1 (de) | 2000-05-31 | 2001-05-31 | Verfahren zur reinigung von alphaviralen replikon partikeln |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6767699B2 (de) |
| EP (1) | EP1285080B1 (de) |
| AT (1) | ATE409749T1 (de) |
| AU (1) | AU2001275191A1 (de) |
| CA (1) | CA2410948C (de) |
| DE (1) | DE60135983D1 (de) |
| DK (1) | DK1285080T3 (de) |
| ES (1) | ES2312447T3 (de) |
| WO (1) | WO2001092552A2 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
| CA2448066A1 (en) | 2001-05-31 | 2002-12-12 | Chiron Corporation | Chimeric alphavirus replicon particles |
| WO2003023026A1 (en) * | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| US7195905B2 (en) * | 2001-12-10 | 2007-03-27 | Baxter Healthcare S.A. | Enveloped virus vaccine and method for production |
| NZ535944A (en) | 2002-04-30 | 2007-11-30 | Oncolytics Biotech Inc | Viral purification method comprising a simple extraction step in which a detergent is directly added to the cell culture, thereafter, cell debris is removed from the extraction mixture by filtration or centrifugation |
| EP1558282A4 (de) * | 2002-10-01 | 2006-04-19 | Chiron Corp | Zusammensetzungen gegen krebs und infektionskrankheiten und anwendungsverfahren dafür |
| DK2290054T3 (en) | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
| US20040208848A1 (en) * | 2002-12-13 | 2004-10-21 | Smith Jonathan F. | Multi-antigenic alphavirus replicon particles and methods |
| US7442381B2 (en) * | 2003-03-20 | 2008-10-28 | Alphavax, Inc. | Alphavirus replicons and helper constructs |
| ATE432285T1 (de) * | 2003-07-11 | 2009-06-15 | Alphavax Inc | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren |
| DE602005012382D1 (de) * | 2004-05-18 | 2009-03-05 | Alphavax Inc | Von tc-83 abgeleitete alphavirus-vektoren, partikel und verfahren |
| ES2647491T3 (es) | 2004-05-21 | 2017-12-21 | Novartis Vaccines And Diagnostics, Inc. | Vectores del alfavirus para las vacunas del virus de la gripe |
| US7901921B2 (en) | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
| EP1736538A1 (de) * | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Prozess für die preparative Reinigung von Virus-ähnlichen Partikeln (VLPs) |
| KR100760525B1 (ko) * | 2006-04-13 | 2007-10-04 | 김재만 | 병원성 미생물의 무증폭 다중 정량 검출킷트 및 검출방법 |
| US20090022760A1 (en) | 2006-09-12 | 2009-01-22 | Alphavax | Alphavirus Replicon Particles Matched to Protein Antigens as Immunological Adjuvants |
| EP2066346B1 (de) | 2006-09-12 | 2019-07-03 | AlphaVax, Inc. | Für il-12 kodierende alphavirusreplikationspartikel als immunologische hilfsstoffe |
| NZ576563A (en) * | 2006-11-03 | 2012-09-28 | Alphavax Inc | Alphavirus and alphavirus replicon particle formulations and methods |
| PL2947149T3 (pl) | 2007-06-21 | 2018-09-28 | Alphavax, Inc. | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych |
| WO2010065414A1 (en) | 2008-12-01 | 2010-06-10 | Alphavax, Inc. | Use of micrornas to control virus helper nucleic acids |
| AU2010203223B9 (en) | 2009-01-05 | 2015-10-08 | Epitogenesis Inc. | Adjuvant compositions and methods of use |
| US10072307B1 (en) | 2009-01-23 | 2018-09-11 | Colorado State University Research Foundation | Isolation of viruses using anionic resin beads |
| WO2010118252A1 (en) | 2009-04-08 | 2010-10-14 | Alphavax, Inc. | Alphavirus replicon particles expressing trp2 |
| KR20130031351A (ko) | 2010-07-30 | 2013-03-28 | 이엠디 밀리포어 코포레이션 | 크로마토그래피 매질 및 방법 |
| EP2625264B1 (de) | 2010-10-08 | 2022-12-07 | Terumo BCT, Inc. | Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen |
| US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| WO2015073913A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
| US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
| KR102072529B1 (ko) | 2014-09-02 | 2020-02-25 | 이엠디 밀리포어 코포레이션 | 나노-피브릴화된 표면 특징을 갖는 고표면적 섬유 매질 |
| US20160090569A1 (en) | 2014-09-26 | 2016-03-31 | Terumo Bct, Inc. | Scheduled Feed |
| WO2016093926A1 (en) | 2014-12-08 | 2016-06-16 | Emd Millipore Corporation | Mixed bed ion exchange adsorber |
| WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
| DK3393510T3 (da) | 2015-12-23 | 2023-03-13 | Valneva Austria Gmbh | Zikavirusvaccine |
| EP3464565A4 (de) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Zellexpansion |
| US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
| US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
| US11629332B2 (en) | 2017-03-31 | 2023-04-18 | Terumo Bct, Inc. | Cell expansion |
| US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
| CA3073234A1 (en) | 2017-09-21 | 2019-03-28 | Valneva Se | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 |
| NL2022538B1 (en) | 2019-02-08 | 2020-08-19 | Academisch Ziekenhuis Groningen | Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof. |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466788A (en) * | 1985-03-07 | 1995-11-14 | Mycogen Plant Science, Inc. | Subgenomic promoter |
| ES8800988A1 (es) | 1985-04-05 | 1987-12-16 | Meloy Lab | Procedimiento de producir interferona humana. |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| WO1988000472A1 (en) | 1986-07-23 | 1988-01-28 | Aphton Corporation | Immunogens and improved methods of making immunogens |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5093239A (en) | 1988-05-02 | 1992-03-03 | Eastman Kodak Company | Reagents for detecting oxidase positive microorganisms |
| US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
| US5026686A (en) | 1989-02-01 | 1991-06-25 | Washington University | Antiviral peptides |
| US5185440A (en) | 1989-06-20 | 1993-02-09 | North Carolina State University | cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof |
| EP1001032A3 (de) | 1989-08-18 | 2005-02-23 | Chiron Corporation | Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern |
| EP0554376A4 (en) | 1990-10-22 | 1994-08-24 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US5279823A (en) * | 1992-06-08 | 1994-01-18 | Genentech, Inc. | Purified forms of DNASE |
| WO1994017813A1 (en) | 1993-02-08 | 1994-08-18 | Paravax, Inc. | Defective sindbis virus vectors that express toxoplasma gondii p30 antigens |
| DE4315109A1 (de) | 1993-05-06 | 1994-11-10 | Inst Pflanzengenetik & Kultur | Verfahren und Vektorkonstrukt zur Expressionssteigerung von Transgenen |
| EP0647716B1 (de) | 1993-07-06 | 2003-09-24 | Universite De Nice-Sophia Antipolis | Vektor, enthält ein bei ARN-Polymerase-III transcriptes Virus-Gen |
| US5837503A (en) | 1993-07-07 | 1998-11-17 | Universite De Nice-Sophia-Antipolis | Vector containing viral gene transcribed by RNA polymerase III and methods for use |
| EP0814154B1 (de) * | 1993-09-15 | 2009-07-29 | Novartis Vaccines and Diagnostics, Inc. | Rekombinante Alphavirus-Vektoren |
| US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
| US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
| IL112371A0 (en) | 1994-01-25 | 1995-03-30 | Res Dev Foundation | A novel protein from aedes albopictus cells and methods for its use |
| US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
| US5532154A (en) | 1994-03-21 | 1996-07-02 | Research Development Foundation | Mutated alpha virus |
| SE9401091D0 (sv) | 1994-03-31 | 1994-03-31 | Bioption Ab | Alphavirus cDNA vectors |
| GB9406498D0 (en) | 1994-03-31 | 1994-05-25 | Smithkline Beecham Biolog | Novel compounds |
| SE9401709D0 (sv) | 1994-05-18 | 1994-05-18 | Mathilda Sjoeberg | Improved alphavirus vectors for expression of heterologous DNA |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| WO1996017072A2 (en) | 1994-11-30 | 1996-06-06 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5837520A (en) * | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| US5792462A (en) | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5797870A (en) | 1995-06-07 | 1998-08-25 | Indiana University Foundation | Pericardial delivery of therapeutic and diagnostic agents |
| US6143548A (en) | 1995-08-30 | 2000-11-07 | Genzyme Corporation | Chromatographic purification of adeno-associated virus (AAV) |
| WO1997016169A1 (en) | 1995-11-01 | 1997-05-09 | Chiron Corporation | Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space |
| EP0871747A1 (de) | 1996-01-02 | 1998-10-21 | Chiron Viagene, Inc. | Immunstimulierung vermittelt durch genmodifizierte dendritische zellen |
| WO1997030155A1 (en) | 1996-02-15 | 1997-08-21 | Chiron Corporation | Gene therapy method using fgf-5 |
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| DE69738521T2 (de) | 1996-04-05 | 2009-05-07 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Alphaviren-vektors mit einer reduzierten inhibierung der synthese von zellmakromolekülen |
| AU3210997A (en) | 1996-05-24 | 1997-12-09 | University Of Maryland At Baltimore | Dna vaccines for eliciting a mucosal immune response |
| US5843712A (en) | 1996-06-06 | 1998-12-01 | The Trustees Of Columbia University In The City Of New York | Sindbis virus expression system for recombinant antibody production |
| US6489167B1 (en) | 1996-09-25 | 2002-12-03 | The Government Of The United States As Represented By The Secretary Of The Department Of Human Services | Retroviral packaging cassettes amplified in the cytoplasm by autocatalytic Togavirus vectors |
| AU729690B2 (en) | 1996-10-10 | 2001-02-08 | Henrik Garoff | Alphavirus-retrovirus vectors |
| AU7637796A (en) | 1996-12-09 | 1998-07-03 | James Edwin Bailey | Expression of active interferon beta 1 using recombinant rna replicons |
| US6261823B1 (en) * | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
| US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
| US6261570B1 (en) | 1997-05-20 | 2001-07-17 | The United States Of America As Represented By The Secretary Of The Army | Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants |
| WO1999009192A1 (en) | 1997-08-15 | 1999-02-25 | Inex Pharmaceuticals Corporation | Semliki forest virus vectors for gene transfer into non-endothelial cardiovascular cells |
| US6060308A (en) | 1997-09-04 | 2000-05-09 | Connaught Laboratories Limited | RNA respiratory syncytial virus vaccines |
| AU747438B2 (en) | 1997-09-24 | 2002-05-16 | Regents Of The University Of California, The | Non-primate lentiviral vectors and packaging systems |
| AU753729B2 (en) | 1997-11-14 | 2002-10-24 | Connaught Laboratories Limited | Alphavirus vectors |
| US20030180257A1 (en) | 1997-11-14 | 2003-09-25 | Mark Parrington | Alphavirus vectors for paramyxovirus vaccines |
| EP1039926A1 (de) | 1997-12-18 | 2000-10-04 | G.D. SEARLE & CO. | Venezuelan equine encephalitis virus vektor der tumor-assoziierte antigene exprimiert zur induktion von krebsimmunität |
-
2001
- 2001-05-31 US US09/872,086 patent/US6767699B2/en not_active Expired - Fee Related
- 2001-05-31 DE DE60135983T patent/DE60135983D1/de not_active Expired - Lifetime
- 2001-05-31 AU AU2001275191A patent/AU2001275191A1/en not_active Abandoned
- 2001-05-31 ES ES01941874T patent/ES2312447T3/es not_active Expired - Lifetime
- 2001-05-31 EP EP01941874A patent/EP1285080B1/de not_active Expired - Lifetime
- 2001-05-31 AT AT01941874T patent/ATE409749T1/de active
- 2001-05-31 CA CA2410948A patent/CA2410948C/en not_active Expired - Fee Related
- 2001-05-31 DK DK01941874T patent/DK1285080T3/da active
- 2001-05-31 WO PCT/US2001/018021 patent/WO2001092552A2/en active Application Filing
-
2004
- 2004-06-29 US US10/881,575 patent/US20050112752A1/en not_active Abandoned
-
2008
- 2008-09-18 US US12/212,978 patent/US20100055128A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/430,920 patent/US20120231526A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1285080B1 (de) | 2008-10-01 |
| AU2001275191A1 (en) | 2001-12-11 |
| US20020015945A1 (en) | 2002-02-07 |
| CA2410948C (en) | 2012-07-17 |
| WO2001092552A3 (en) | 2002-05-23 |
| US6767699B2 (en) | 2004-07-27 |
| CA2410948A1 (en) | 2001-12-06 |
| EP1285080A2 (de) | 2003-02-26 |
| US20050112752A1 (en) | 2005-05-26 |
| ES2312447T3 (es) | 2009-03-01 |
| US20100055128A1 (en) | 2010-03-04 |
| DE60135983D1 (de) | 2008-11-13 |
| US20120231526A1 (en) | 2012-09-13 |
| WO2001092552A2 (en) | 2001-12-06 |
| DK1285080T3 (da) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE409749T1 (de) | Verfahren zur reinigung von alphaviralen replikon partikeln | |
| DK0561890T3 (da) | DNA ekspressionssystemer baseret på alphavira | |
| DK1751289T3 (da) | TC-83-afledte alfavirus-vektorer, partikler og fremgangsmåder | |
| BRPI0408424B8 (pt) | ácido nucleico de replicon recombinante, população de partículas de alfa-vírus infecciosas e defeituosas, composição farmacêutica, partícula de alfa-vírus, célula microbiana e método in vitro para produzir partículas de alfa-vírus infecciosas e defeituosas | |
| WO2005035556A3 (en) | Sars-coronavirus virus-like particles and methods of use | |
| FI964592A0 (fi) | Papilloomavirusrokotteita | |
| ATE432285T1 (de) | Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren | |
| ATE384785T1 (de) | Herstellung von viren, virusisolaten, und impfstoffen | |
| DE60044665D1 (de) | Her2/neu fusionsproteine | |
| DK1062226T3 (da) | Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein | |
| IN2015DN02546A (de) | ||
| DK1519944T3 (da) | Fremgangsmåder til fremstilling af fibrinogen | |
| SG11201903042VA (en) | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome | |
| EA202190907A1 (ru) | Репликоны на основе альфавируса для введения биотерапевтических средств | |
| ATE302268T1 (de) | Methode zur gewinnung und reinigung von poxviren aus infizierten zellen | |
| HK1074643A1 (en) | Recombinant mva capable of expressing structural hcv antigens | |
| ATE321853T1 (de) | Humanische pellino-polypeptide | |
| DE60118739D1 (de) | Verfahren zur isolierung eines proteins | |
| MX2018012858A (es) | Metodo mejorado para producir particulas similares a virus. | |
| ATE408013T1 (de) | Infektiöses cdna klon des gb-virus b und dessen verwendungen | |
| ATE381351T1 (de) | Anwendung des herpes simplex virus glykoproteins- d zur unterdrückung von immunantworten | |
| WO2008027560A3 (en) | Holin-enhanced vaccines and reagents, and methods of use thereof | |
| ATE479705T1 (de) | Reduzierter slam abhängiger zell eintritt | |
| BRPI0417126A (pt) | partìcula viral constituìda de elementos estruturais não provenientes de um alfa-vìrus e contendo um vetor derivado de alfa-vìrus, utilização da partìcula viral e processo de obtenção de partìculas virais | |
| ATE263234T1 (de) | Veränderte, kleine rna-viren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1285080 Country of ref document: EP |